CONNECT WITH US
HealthTech

HealthTech

Former OpenAI science lead launches Warp Science to automate wet labs with robots

TechCrunch — Biotech & Health logo

Published on

Add as a preferred source on Google
Former OpenAI science lead launches Warp Science to automate wet labs with robots

Former OpenAI science lead Kevin Weil has launched Warp Sciences, a new AI startup focused on automating lab work for drug discovery. The company, which trains robots to make and test promising compounds identified by researchers, has raised $215 million at an $865 million valuation, according to Weil, who announced the startup and funding on X.

The round was led by Lightspeed, with participation from IVP, Premji Invest, and Lux Capital.

For years, biotech companies have outsourced the most labor-intensive work of synthesizing thousands of variations of molecules to contractors in China, such as WuXi AppTec. With Warp Sciences, Weil hopes to reshore that work and insulate the entire drug development process from geopolitical supply-chain risks.

Wearing cameras and sensor gloves, the startup’s human chemists will train robots to perform various lab tasks. By automating wet-lab work, Warp Sciences aims to accelerate drug discovery using robots that can operate around the clock.


Buy One Pass, Get a Second Free

Cover more ground at TechCrunch’s ultimate founder bootcamp of the year by bringing your co-founder or partner for free

Book before the BOGO deal expires



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.